Omnicell (NASDAQ:OMCL) Issues Q4 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.55-$0.62 for the period, compared to the consensus EPS estimate of $0.47. The company issued revenue guidance of $295-$305 million, compared to the consensus revenue estimate of $287.85 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Stock Up 32.2 %

Omnicell stock traded up $12.93 during mid-day trading on Wednesday, hitting $53.05. The company had a trading volume of 2,646,279 shares, compared to its average volume of 524,859. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. The stock's 50 day moving average price is $42.95 and its two-hundred day moving average price is $34.95. The company has a market capitalization of $2.44 billion, a PE ratio of -113.13, a price-to-earnings-growth ratio of 43.55 and a beta of 0.83.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million for the quarter, compared to analysts' expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell's revenue was down 7.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 EPS. As a group, sell-side analysts anticipate that Omnicell will post 0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company upped their price objective on Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research report on Monday, October 14th. Barclays raised Omnicell from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on Omnicell from $26.00 to $37.00 and gave the stock a "neutral" rating in a research report on Friday, August 23rd. Bank of America upped their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Finally, Benchmark reiterated a "buy" rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $41.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.